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Electrophysiological characterisation of central
sensitisation in canine spontaneous osteoarthritis
James R. Hunta,*, Megan Goffa, Helen Jenkinsa, John Harrisb, Toby G. Knowlesa, B. Duncan X. Lascellesc,d,e,f,
Masataka Enomotoc, Michael Mendla, Helen R. Whaya, Joanna C. Murrella
Abstract
In man, central sensitisation (CS) contributes to the pain of osteoarthritis (OA). Dogs with spontaneous OA may also exhibit CS.
Electrophysiological reflex measurements are more objective than behavioural assessments and can be used to evaluate CS in
preclinical and clinical studies. It was hypothesised that dogs suffering from OA would exhibit electrophysiological characteristics
indicative of CS, associated with reduced diffuse noxious inhibitory controls (DNICs). One hundred and seventeen client-owned dogs
were recruited to the study. Hind limb nociceptive withdrawal reflex thresholds, stimulus response, and temporal summation
characteristics were recorded, during alfaxalone anaesthesia, from 46 OA dogs, 29 OA dogs receiving nonsteroidal anti-inflammatory
drugs (OANSAIDs), and 27 breed- and weight-matched control dogs. Efficacy of DNIC was evaluated in 12 control and 11 of the OA
dogs, by application of a mechanical conditioning stimulus to the contralateral forelimb. Nociceptive withdrawal reflex thresholds were
higher in OA compared with control dogs (P 5 0.02). Stimulus response characteristics demonstrated an augmented response in
OANSAID dogs compared with OA (P , 0.001) and control (P , 0.001) dogs. Temporal summation demonstrated exaggerated C-
fibre-mediated responses in both OA (P , 0.001) and OANSAID (P 5 0.005) groups, compared with control animals. Conditioning
stimulus application resulted in inhibition of test reflex responses in both OA and control animals (P , 0.001); control animals
demonstrated greater inhibition compared with OA (P 5 0.0499). These data provide evidence of neurophysiological changes
consistent with CS in dogs with spontaneous OA and demonstrate that canine OA is associated with reduced DNIC.
Keywords: Central sensitisation, Diffuse noxious inhibitory controls, Dog, Nociceptive withdrawal reflex, Osteoarthritis
1. Introduction
Spontaneous canine osteoarthritis (OA) has been proposed as
a model of human OA.38 In man, in addition to mechanisms local
to affected joints, central sensitisation (CS) may exacerbate
pain.29 Some dogs affected by OA respond to centrally acting
antihyperalgesic drugs26 and have altered nociceptive thresh-
olds,21 suggesting CS; however, there is no “gold standard”
approach for identifying and quantifying CS in dogs. Therefore, it
is currently unknown whether OA in dogs is also associated with
CS, yet this information is essential if canine OA is to be used as
a valid model of human OA.
The RIII withdrawal response threshold and magnitude, and
temporal summation (TS) to repeated stimuli are altered in pain
syndromes associated with CS in man and may be used as
objective markers of CS.37 In dogs, the nociceptive withdrawal
reflex (NWR)6 and TS of the NWR8 have been suggested as
potential biomarkers for CS. We have previously developed
methods to evaluate these measures during anaesthesia.19 There
are, presently, no reports of alterations in NWR or TS associated
with painful disease in dogs, and the potential for the technique to
characterise the state of spinal excitability remains untested.
Diffuse noxious inhibitory controls (DNIC) represent an endoge-
nous supraspinal antinociceptive mechanism activated by hetero-
topic noxious (“conditioning”) stimulation.5,15 Efficacy of conditioned
pain modulation (CPM) in man (considered the equivalent of DNIC) is
a predictor of acute14 and chronic postoperative41 pain, and is
commonly reduced in chronic pain states, including OA.2 There are
no investigations of DNIC efficacy associated with OA in dogs.
Conditioned pain modulation may be modulated by cognitive
influences,30 which are challenging to control for experimentally.
Therefore, it is desirable to develop a non–tissue-damaging
paradigm, which may be applied to anaesthetised animals.
The primary aim of the studies described here was to compare
electrophysiological responses, including TSof C-fibre responses, in
a cohort of client-owned pet dogs suffering from spontaneous OA,
with a matched group of control pet dogs. Dogs within the OA
cohort were divided into those receiving daily nonsteroidal
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anti-inflammatory drugs (NSAIDs) to manage OA-associated
pain (OA dogs receiving nonsteroidal anti-inflammatory drugs
[OANSAIDs]) and dogs not receiving drug treatment (OA). We
hypothesised that dogs with OA would exhibit electrophysiological
characteristics indicative of CS, and that these characteristics
would be exaggerated in the OANSAID group compared with the
OAgroupbecauseof the greater pain thatwas likely experiencedby
OANSAID dogs, despite ongoing NSAID administration.
Our second aim was to develop an effective protocol to
evaluate DNIC in dogs. Conditioned pain modulation has been
elicited by mechanical conditioning stimulation (MCS)33; there-
fore, we sought to investigate whether MCS would evoke DNIC,
and whether DNIC efficacy was decreased by OA. We
hypothesised that in control dogs, application of MCS would
inhibit the NWR, and that the degree of inhibition would be
reduced in dogs affected by OA.
2. Methods
2.1. Nociceptive withdrawal reflex/temporal
summation investigation
2.1.1. Ethics
The study was conducted under the terms of the Animal
(Scientific Procedures) Act, 1986 (as amended, 2013) (A(SP)A)
licence number PPL 30/3157, and the experimental protocol was
approved by the University of Bristol Animal Welfare and Ethical
Review Body.
2.1.2. Recruitment criteria
Advertisements to recruit participants for the study were posted
on social media (Facebook and Twitter), within the local University
of Bristol intranet, andwithin local veterinary practices. For the OA
group, suitable dogs were 12 kg body weight and above, of any
age, body condition and sex exhibiting suspected painful
unilateral or bilateral coxofemoral or stifle degenerative joint
disease as evidenced by lameness/stiffness/difficulty in rising or
ascending steps. Dogs with primarily forelimb lameness were
excluded. During the study recruitment phase, a large proportion
of dogs screened were already receiving daily treatment with
NSAIDs for musculoskeletal pain, and the decision was made to
recruit these animals and permit them to continue daily NSAID
treatment, but to designate them as a separate group (OANSAID)
for analysis within the study. This decision was based on the fact
that pain and disability were still present in these individuals,
despite treatment with the NSAID.
The inclusion criteria for the control group were based on the
demographics of a cohort of OAdogs recruited to a separate study
at the University of Bristol,16 where a mean (SD) age of 9.5 6 3
years and weight of 27.56 11.6 kg were recorded. For this study,
dogs were recruited to the control group that were 6 years old or
Figure 1. Illustration of the number of animals recruited to each OA category and attrition through different stages of the study. DNIC, diffuse noxious inhibitory
control; EMG, electromyography; NWR, nociceptive withdrawal reflex; OA, osteoarthritis; OANSAID, OA dogs receiving nonsteroidal anti-inflammatory drug; TS,
temporal summation.
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greater and 12 kg body weight and above, exhibiting no evidence
of lameness or stiffness and with no other painful condition (eg,
otitis externa) and no previous diagnosis of OA. Figure 1 illustrates
the outcomes for all dogs that attended screening and the
subsequent numbers that were used at each stage of the study.
2.1.3. Study protocol
Owners of eligible dogs were asked to attend a screening
appointment, at which the purpose and procedures of the study
were explained verbally and in writing, and signed consent to
participate was obtained before any study procedures being
performed. Dogs underwent physical and musculoskeletal
examination by a veterinarian (J.R.H.). Body condition score (1,
emaciated—9, morbidly obese24) was assessed by manual
palpation. Any dogs with identifiable comorbidities that would
have increased risks associated with general anaesthesia, or
dogs with neurological dysfunction evidenced by weak or absent
conscious proprioception, were excluded from the study.
Microchip details were confirmed as a means of permanently
identifying participating dogs to comply with the terms of the A
(SP)A. Owners were asked to complete the ACVS Canine
Orthopaedic Index,9 the Helsinki Chronic Pain Index,17 the
Liverpool Osteoarthritis in Dogs (LOAD) questionnaire, the Canine
Brief Pain Inventory (CBPI),10 and the sleep and night time
restlessness evaluation (SNoRE).22 Jugular blood samples were
obtained and submitted for routine biochemistry and haematol-
ogy before scheduling general anaesthesia.
2.1.4. Musculoskeletal examination
Scores for lameness (0-10) and mobility (0-3) were assigned by
a veterinarian (J.R.H.), according to the criteria shown in
Appendix 1 (available online as supplemental digital content at
http://links.lww.com/PAIN/A622).
Examination of each joint was performed, and individual
appendicular joints were scored from 0 (not affected) to 3
(severely affected) for the criteria “range of motion,” “pain on
extension or flexion,” “crepitus,” “effusion,” and “thickening.” The
sum of the joint disease scores produced an overall OA score
between 0 and 192, whereas the sum of the pain scores for each
joint produced an overall joint pain score between 0 and 48.
2.1.5. General anaesthesia
Seven days after the initial screening appointment, dogs were
admitted to the Wellcome Comparative Anaesthesia Research
Laboratory, Langford, Bristol, to undergo radiography and NWR
testing under general anaesthesia.
On admission, confirmation that dogs had had food withheld
for 8 hours was sought from owners and a veterinary examination
was repeated.
Acepromazine (ACP 2 mg/mL solution; Elanco Animal Health,
Basingstoke, United Kingdom) was administered intramuscularly
(0.03 mg/kg), and dogs were left undisturbed for 30 minutes,
following which a cephalic venous catheter was placed. In-
sufficient sedation to permit intravenous catheterisation war-
ranted exclusion from the study.
Alfaxalone (Alfaxan; Jurox [UK] Ltd, Crawley, United Kingdom) (1-2
mg/kg) was administered intravenously over a period of 60 seconds
until orotracheal intubation was possible. Oxygen was delivered
through a circle breathing system and anaesthesia maintained with
a constant rate infusion of alfaxalone (0.1 mg/kg/min) during
radiography, reducing to 0.09 mg/kg/min for NWR testing. Body
temperature was monitored every 30 minutes and supported with
insulated electric blankets. After NWR testing, alfaxalone infusionwas
discontinued and the dogs constantly monitored until they were
discharged to theowner once able towalk andhaving eaten. All dogs
not ordinarily receiving NSAIDs were treated with meloxicam
(Metacam5mg/mLsolution; Boehringer Ingelheim,Bracknell, United
Kingdom) (0.2 mg/kg) to treat any pain caused by positioning for
radiography or NWR recording.
2.1.6. Radiography
Lateral and cranial–caudal views of the elbows and stifles; lateral
views of the lumbosacral junction; and ventrodorsal views of the
pelvis and coxofemoral joints were obtained in the Bristol
Veterinary School imaging suite. Each of these 7 joints was
assessed for severity of radiographic OA by 2 investigators (M.E.
and B.D.X.L.) who were unaware of the OA group classification of
the dogs. The investigators assigned scores from 0 (no radio-
graphic signs of OA) to 10 (severe radiographic OA) for each joint,
and thus, a global score for each dog out of 70was recorded. The
investigators performing NWR testing remained unaware of the
results of the radiographs.
2.1.7. Nociceptive withdrawal reflex testing
Dogs were positioned in left lateral recumbency with the right
pelvic limb resting on a sandbag, perpendicular to the table top.
Paired stimulating electrodes (disposable subdermal needle
electrode 12 3 0.40 mm; Natus Neurology Inc, Middleton, WI)
were placed 10 mm apart subdermally into the plantar aspect of
digit 3 of the right hind limb; paired recording electrodes were
placed 20 mm apart into the body of the right cranial tibial (CT)
muscle; and a ground electrode placed subcutaneously dorsal to
the dorsal spinous process of L6. As previously described,23 the
recorded signal was processed through a differential amplifier
(DAM50; World Precision Instruments, Herts, United Kingdom),
which applied a band-pass filter from 10 to 1 kHz and gain of
1000, andwas subsequently captured in Labchart 8 software (AD
Instruments, Oxford, United Kingdom) following conversion by an
analogue to digital converter with a sampling frequency of 1 kHz
(Powerlab 4/35; AD instruments).
2.1.8. Electromyographic threshold
Electrical stimuli were delivered through the toe electrodes using
a constant current stimulator from an isolated 100 V source
(Stimulus isolator FE180; AD instruments).
The threshold current at which a single 1-ms square wave
stimulating pulse would evoke a visually discernable CT
electromyographic (EMG) response (a response greater than
the baseline amplitude) was identified by increasing current
stepwise from 0 to a maximum of 10 mA in 0.5-mA increments.
After a response, the current was decreased by 0.1 mA incre-
ments until the responsewas no longer elicited. This up and down
adjustment was continued until 3 stable readings for threshold
were obtained at 60-second intervals.
2.1.9. Stimulus response curve
One stimulus event comprised five 1-msstimuli (Train-of-5 [To5]23),
which were delivered at a frequency of 100 Hz. An EMG stimulus
response determination was performed by triggering To5 events at
60-second intervals using currents of 0.1 (baseline), 1, 2, 3, 4, 5, 6,
7, 8, 9, and 10mA. The complete series of stimulating currentswas
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applied in the same ascending order on a second occasion after
a 5-minute interval.
2.1.10. Temporal summation
A stimulus sequence of 83 1ms 10-mA stimuli delivered at a rate
of 1 Hz was repeated 3 times at 5-minute intervals.
2.1.11. Electromyographic analysis
After recording, a 10-Hz high-pass digital filter was applied to the
EMG traces, to further decrease movement artefact. The primary
outcome measure for the study was the integral of the rectified
EMG response that was extracted for each stimulus within each
predefined time window. The EMG response was designated as
early (representing an A-fibre response 0-100 ms) or late (C fibre;
100-500 ms) latency, time locked to the start of the stimulus
train.23 Although the late responsemay also contain components
of supraspinal origin, this differentiation was based on previous
work in dogs8 where conduction velocity of the different nerve
fiber types and the length of the afferent distance were used to
calculate latency ranges for the different (A and C fiber)
responses. Baseline activity in the absence of any electrically
evoked response (the 0.1-mA stimulus for the stimulus response
experiments and from within a 2-second period before applica-
tion of the first of the 8 stimuli for TS experiments) was subtracted
from each measurement.
2.1.12. Statistical methods
Recordings of NWR data were visually examined by 2 investigators
(J.R.H. and J.H.) and where no identifiable response could be
appreciated to a stimulation protocol, the data for that protocol for
the individual dog were excluded from the analysis. Sex distribution
data were analysed using x2 tests. Comparisons ofmean ormedian
measures at single time points (eg, body weight, lameness, and
owner-completed metrology instruments) between the 3 groups
were performed using 1-way analysis of variance or Kruskal–Wallis
tests followed by the Tukey (or Dunn) post hoc testing if applicable.
The hierarchical structure of the data comprising the stimulus
response and TS data was accounted for by using multilevel
modelling within the MLwiN statistics package.34 In the case of the
stimulus response data, no transformation of the outcome variable
was necessary, as the residuals from the analyses showed
appropriate normality and homoscedasticity. It was necessary to
apply natural log transformation to the TS data to meet the
assumptions of the statistical models. Data analysed using para-
metric tests are presented as mean (95% confidence interval [CI]),
and the results of nonparametric testing are presented as median
(25%-75% interquartile range). The final multilevel general linear
models took the form of equations that described the effect of the
statistically significant predictor variables on the outcomemeasures.
The parameter estimates from the analyses are presented below,
and the models are represented as graphs.
2.1.13. Power calculation
A power calculation for the overarching project, based on
preliminary data using von Frey mechanical threshold data,
indicated a total of 68 dogs, evenly divided between OA and
control groups, would be required for a power of 90%, at an alpha
of 0.05 to detect a difference between control and OA dogs.
However, this calculation assumed uniformity within the OA
group, whereas we suspected that the OA group would be
heterogenous, based on data from human OA patients and
laboratory animal models of OA. In humans, up to 70%of patients
with OA have at least one somatosensory abnormality.40 Based
on this, we estimated that recruiting 100 OA dogs would give us
an appropriate cohort of CS-negative dogs (ie, approximately the
same number as control dogs) and a cohort of CS-positive dogs
that may be as large as 70.
2.2. Diffuse noxious inhibitory control investigation
2.2.1. Animals
After completion of the NWR/TS protocol described above, some
dogs underwent DNIC investigations during the same anaes-
thetic period (Fig. 1).
2.2.2. Diffuse noxious inhibitory control protocol
Five minutes after the final TS experiment, the DNIC protocol
began by recording EMG responses in the CT muscle to test
stimuli delivered at twice the individually determined threshold
current (2xThr) at a rate of 1 Hz for 100 seconds. This occasion
was denoted as “pre-DNIC.” An identical test stimulation protocol
(2xThr, 1 Hz, 100 seconds) was repeated on 3more occasions at
5-minute intervals; however, during occasions 2 (“DNIC 1”) and 3
(“DNIC 2”), the effect on CT responses of an additional
mechanical conditioning stimulus, comprising a bulldog clip
applied for 20 seconds to the third digit of the contralateral
forelimb, was assessed (Fig. 2). The fourth and final occasion
(“post-DNIC”) was a repeat of the pre-DNIC stimulating protocol,
without the addition of a conditioning stimulus.
Measurement of the force delivered by the bulldog clip at a jaw
separation of 11 mm (mean jaw opening measured during the
application to the digit) was achieved using a Loadcell 50 N gauge
(Mecmesin; Slinfold, West Sussex, United Kingdom). The force
recorded by the gauge at 11-mm separation was 33.4 N, but this
was also found to be consistent over the range of jaw opening
from 2 to 12 mm. Examination of the site of application following
theDNIC protocol, and 7 days later, demonstrated no evidence of
immediate or delayed ongoing pain or tissue damage.
2.2.3. Statistical methods
Sex distribution data were assessed using the Fisher exact test.
Comparisons ofweight and owner-completedmetrology instrument
scores between the 2 groups were performed using the Student t
test or Mann–Whitney U test. The hierarchical structure of the DNIC
testing datawas accounted forwithin the statistical analysis by using
general linear modelling within a multilevel modelling framework
using the MLwiN statistics package.41 Predictor variables were
retained within the model based on a Wald test at a # 0.05. It was
necessary to apply a natural log transformation to the EMG
magnitude data, to meet the assumptions of the tests regarding
normality and homoscedasticity of residuals. The pre-DNIC
occasion was denoted as the reference occasion for comparisons
within the model. Data subject to parametric tests are presented as
mean (95% CI) and results subject to nonparametric testing are
presented as median (25%-75% interquartile range).
2.2.4. Power calculation
A power calculation was performed for the overarching project;
however, the DNIC investigation was performed to develop an
effective but non–tissue-damaging model for evaluating DNIC in
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dogs, and to provide pilot data for ongoing investigations, hence
a power calculation was not performed specifically regarding the
primary outcome measure (magnitude of EMG response)
reported here.
3. Results
3.1. Nociceptive withdrawal reflex/temporal
summation investigation
3.1.1. Demographics
Data were analysed from 27 control, 46 OA, and 29 OANSAID
dogs. Breed and sex distribution are shown inTable 1. There was
no significant difference in sex distribution, and breed distribution
appeared to be visually well matched between groups. Weight
and body condition scores were not different between groups
(Table 1). Dogs in the control group were younger than dogs in
both the OA and OANSAID groups (Table 1). The duration of
NSAID treatment in the OANSAID group was variable between
individuals, but animals had been receiving daily NSAIDs for at
least 3 months before recruitment to the study.
3.1.2. Veterinary assessment
Degree of lameness, mobility score, total OA score, and total joint
pain score were all significantly higher in OA and OANSAID groups
compared with controls (Table 2); however, there were no differ-
ences between OA and OANSAID groups regarding these
measures.
3.1.3. Owner-completed clinical metrology instruments
Questionnaire data were analysed by subsection if the questionnaire
was constructed in a section format. Owner-attributed scores for all
the questionnaire subsections were significantly higher (more
dysfunction/pain) in OA and OANSAID animals compared with
controls. In addition, the CBPI pain and ACVS function subsections
were significantly higher in OANSAID compared with OA animals
(Table 2), indicating that dogs receiving NSAID therapy experienced
greater pain and greater dysfunction (eg, reduced mobility) than
dogs with OA that were not receiving NSAID treatment.
3.1.4. Radiographic scores
Radiographic OA severity was significantly higher in both OA and
OANSAID animals compared with controls but was not signifi-
cantly different between OA and OANSAID animals (Table 2).
3.1.5. Nociceptive withdrawal reflex recordings
The early phase of the NWR could be reliably and repeatedly
elicited in the CTmuscle during themultiple trials at each stimulus
intensity. Examples of raw traces obtained during NWR recording
are provided (Figs. 3 and 4).
3.1.6. Electrical threshold
The threshold current to elicit an EMG response was significantly
lower in control (2.3 [95% CI 1.8-2.9 mA]) compared with OA
dogs (3.8 [95% CI 3.0-4.6 mA] [F2,93 5 3.859, P 5 0.02]), but
neither group was different from OANSAID (3.2 [95% CI 2.4-3.9
mA]) that had an intermediate value.
3.1.7. Stimulus response
Only the early component of the response was analysed, as the
late response was absent in the majority of recordings (Table 3).
Figure 2.During anaesthesia, a bulldog clip conditioning stimulus was applied
for 20 seconds to the third digit of the left cranial limb, whereas electrical test
stimuli were delivered to the right pelvic limb.
Table 1
Demographic data.
Control
(n 5 27)
OA (n 5 46) OANSAID
(n 5 29)
P
Breed
Border collie 7 10 5 —
Labrador 5 8 11 —
Retriever 3 3 1 —
Lurcher 3 2 0 —
Spaniel 1 5 3 —
Other 8 18 9 —
Sex
M 3 3 3 0.61
Mn 7 18 14 0.61
F 1 3 2 0.61
Fn 16 22 10 0.61
Weight (kg) 22.8 (95% CI
20.5-25.0)
26.8 (95% CI
23.6-29.9)
28.7 (95% CI
24.8-32.6)
0.0563
Body condition
score (1-9)
5 (4-6) 5 (5-6) 5 (4-6) 0.19
Age (y) 7.8 (95% CI
7.3-8.4)a
9.8 (95% CI
9.2-10.3)b
9.6 (95% CI
8.5-10.6)b
,0.001***
Superscript letters indicate groupings within the data, shared superscripts indicate no significant difference
between groups on post hoc testing, and differing superscripts indicate a difference with a P value of less than
0.05 on post hoc testing. ***P # 0.001.
F, female; Fn, female neuter; M, male; Mn, male neuter; OA, osteoarthritis; OANSAID, OA dogs receiving
nonsteroidal anti-inflammatory drug.
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The parameter estimates of those predictor variables significantly
associated with the response are presented in Table 3. The final
model, containing only the significant terms, demonstrated that
the magnitude of the measured response increased as a curvi-
linear function of the stimulating current (mA). There was
a significant negative interaction between body weight and
stimulating current (weight.mA; P , 0.001); larger animals
demonstrated a lesser increase in response magnitude with
increasing current compared with smaller animals. There was
a significant positive interaction between the OANSAID category
and stimulating current (OANSAID.mA) compared with control (P
, 0.001) and OA category (P , 0.001) animals; OANSAID
category animals demonstrated increased magnitude responses
at a given stimulating current, comparedwith both control andOA
category animals. These relationships are shown graphically in
Figure 5, at a fixed weight of 25 kg.
3.1.8. Temporal summation early (A-fibre) response
The magnitude of A-fibre responses increased with increasing
stimulus number from 1 to 8 within each repetition of the protocol
(TS) (P , 0.001) but was reduced on the third (final) occasion of
the TS (train of 8) protocol, compared with the first (P 5 0.013)
(Table 4). Higher weight animals demonstrated reduced magni-
tude responses to stimulation (P5 0.001) and lesser increases in
magnitude of response with increasing stimulus number (weight.
stimulus number interaction) (P 5 0.009). Osteoarthritis and
OANSAID animals did not differ from control animals.
Table 2
Musculoskeletal examination, owner-completed metrology instrument, and radiographic severity data.
Control OA OANSAID P
Lameness (0-10) 0 (0-0)a 3 (1-3)b 3 (2-3)b,c ,0.001***
Mobility (0-3) 0 (0-0)a 1 (1-1)b 1 (1-1)b,c ,0.001***
OA score (0-192) 0 (0-2)a 10 (7-16)b 14 (9-19)b,c ,0.001***
Joint pain score (0-48) 0 (0-0)a 4 (2-4)b 4 (3-5)b,c ,0.001***
CBPI pain (0-10) 0 (0-0.0625)a 1.75 (0-3.5)b 3.375 (1.813-4.688)c ,0.001***
CBPI function (0-10) 0 (0-0.833)a 1.167 (0.1667-4.50)b 2.833 (1.50-5.042)b,c ,0.001***
HCPI (0-44) 3 (0-8.25)a 14 (8-22)b 20.5 (15.25-21.75)b,c ,0.001***
ACVS stiffness (0-16) 0 (0-0.25)a 5 (2-8)b 8 (5-9)b,c ,0.001***
ACVS function (0-16) 0 (0-0.25)a 5 (1-8)b 8 (6-12)c ,0.001***
ACVS gait (0-20) 0.5 (0-2.25)a 7 (2-11)b 9 (7-11.75)b,c ,0.001***
ACVS QoL (0-12) 0 (0-1)a 3 (1-5)b 4.5 (2.6)b,c ,0.001***
LOAD (0-52) 2 (0-5)a 14 (9-23)b 18.5 (12-23)b,c ,0.001***
Radiographic OA score (0-70) 3 (1-10)a 14 (8.25-24.75)b 20 (8-26)b,c ,0.001***
Superscript letters indicate groupings within the data, shared superscripts indicate no significant difference between groups on post hoc testing, and differing superscripts indicate a difference with a P value of less than 0.05 on
post hoc testing. ***P # 0.001.
CBPI, Canine Brief Pain Inventory; HCPI, Helsinki Chronic Pain Index; LOAD, Liverpool Osteoarthritis in Dogs; OA, osteoarthritis; OANSAID, OA dogs receiving nonsteroidal anti-inflammatory drug.
Figure 3. An example of temporal summation in the cranial tibial muscle (recorded from dog 71). The top channel is a stimulus marker channel, with a train of 8,
1-ms 10-mA stimuli delivered at a frequency of 1 Hz. The lower channel shows the early and late responses in the cranial tibial muscle. The time base is 0.2
seconds/division. CT, cranial tibial.
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3.1.9. Temporal summation late (C-fibre) response
The TS protocol consistently elicited late responses (Table 4).
The magnitude of the late (C-fibre) response increased with
increasing stimulus number from 1 to 8 within each repetition of
the protocol (TS) (P , 0.001) but was decreased on both the
second and third occasions of repeating the protocol (train of 8)
compared with the first trial. Higher weight animals demonstrated
lesser increases in magnitude of response with increasing
stimulus number (weight.stimulus number interaction; P ,
0.001), and older animals also demonstrated lesser increases in
magnitude of response with increasing stimulus number (age.
stimulus number interaction; P 5 0.001). Both OA (OA.stimulus
number interaction; P , 0.001) and OANSAID (OANSAID.
stimulus number interaction; P 5 0.005) category animals
demonstrated larger increases in magnitude of response with
increasing stimulus number compared with control animals (Fig.
6), but there were no differences between the OA and OANSAID
groups.
3.2. Diffuse noxious inhibitory control investigation
3.2.1. Demographics
Data were analysed from 12 control and 11 OA dogs (none
receiving NSAIDs). The sex distribution between the groups was
not different, and the distribution of breeds appeared well
matched on visual inspection (Table 5). Osteoarthritis dogs were
significantly older than control dogs (Table 5). Groups were not
different in terms of weight; however, body condition score was
Figure 4. An example of the electrical stimulus response curve recorded from the cranial tibial muscle in dog 98. The top channel is the stimulus marker channel,
with each single line representing five 1-ms stimuli delivered at a frequency of 100 Hz. Eleven stimuli were delivered with a 60-second interval between them
starting at 0.1mA (baseline), 1mA, and increasing in 1mA increments through to 10mA. Themiddle channel shows the early responses in the cranial tibial muscle,
and the lower channel shows the rectified EMG response in the cranial tibial muscle. The time base is 0.2 seconds/division. CT, cranial tibial; EMG,
electromyography.
Table 3
Effect size estimates and P values for the general linear model that was fitted to the stimulus response (early) data.
Response magnitude (mV/s) SE Conf int 2.5% Conf int 97.5% P
Intercept 20.001230 0.003234 20.007569 0.005109 0.704
Weight 0.000018 0.000113 20.000204 0.000240 0.873
OA 0.000753 0.002481 20.004110 0.005615 0.762
OANSAID 0.000353 0.002782 20.005100 0.005806 0.899
mA 0.004864 0.000540 0.003807 0.005922 ,0.001***
mA2 20.000170 0.000052 20.000271 20.000069 0.001**
weight.mA 20.000094 0.000019 20.000132 20.000056 ,0.001***
weight.mA2 0.000004 0.000002 0.000001 0.000008 0.026*
OA.mA 20.000092 0.000119 20.000325 0.000141 0.440
OANSAID.mA 0.000759 0.000134 0.000497 0.001021 ,0.001***
*P # 0.05; **P # 0.01; ***P # 0.001.
OA, osteoarthritis; OANSAID, OA dogs receiving nonsteroidal anti-inflammatory drug.
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higher in OA (6, 5-7) compared with control dogs (5, 4.25-5.75,
P 5 0.047).
3.2.2. Veterinary musculoskeletal and gait assessments
Degree of lameness, mobility impairment, OA burden, and joint
pain burden were all increased in OA compared with control dogs
(Table 6).
3.2.3. Owner-completed clinical metrology instruments
The CBPI, Helsinki Chronic Pain Index, ACVS Canine
Orthopaedic Index, and LOAD were all rated significantly
higher by owners of OA compared with control dogs (Table 6),
but there was no significant difference in scores for the SNoRE
questionnaire.
3.2.4. Radiography
Significantly more radiographic signs of OA were identified in
dogs in the OA compared with control group, and significantly
more of the 7 joints assessed demonstrated radiographic signs of
OA in OA compared with control dogs (Table 6).
3.2.5. Nociceptive withdrawal reflex threshold
The threshold current required to elicit an NWR was significantly
higher in OA (3.8 [95% CI 2.4-5.2 mA]) compared with control
dogs (1.9 [95% CI 1.4-2.5 mA], P 5 0.013) (Table 6).
3.2.6. Diffuse noxious inhibitory control efficacy
The 2xThr stimulation did not elicit consistent late responses,
therefore only the early (0-100 ms) latency response was
analysed.19
The final significant general linear model that described the
magnitude of the early response took the form of an equation,
the parameter estimates of which and P values associated with
the predictor variables within the model are presented in Table 7.
The predictor variables and their relationship with the magnitude
of the response are described below. Time and age were
considered continuous scale variables. Each occasion of DNIC
testing (pre, DNIC 1, DNIC 2, and post) was considered
a categorical variable, as was OA status (OA/control). Figure 7
shows the effect of mechanical “conditioning” stimulation of the
forepaw on electrically evoked “test” EMG reflexes in the CT
muscle of the contralateral hind limb.
3.2.6.1. Stability of response magnitude within occasion
Time alone did not account for a significant variation in magnitude
within a test occasion (P 5 0.069).
3.2.6.2. Stability of response magnitude between occasions
Between different test occasions, response magnitude was
decreased in DNICs 1 and 2, and in the post-DNIC state,
compared with the original pre-DNIC occasion (P 5 0.048,
,0.001, and ,0.001 respectively), indicating a decreasing
magnitude of response with repeated occasions of the stimulat-
ing protocol.
3.2.6.3. Efficacy of diffuse noxious inhibitory control stimulus
There was a significant interaction between time and occasion for
DNICs 1 and 2 (P ,0.001), but not between time and occasion
post-DNIC (P 5 0.50), demonstrating that the application of the
conditioning stimulus was responsible for significantly decreasing
the response magnitude during DNICs 1 and 2 compared with
the pre-DNIC occasion. The interaction between square and
cubic terms of time, and DNICs 1 and 2, was significant,
indicating a curvilinear change of response with application of the
conditioning stimulus.
3.2.6.4. Effect of osteoarthritis status
Osteoarthritis status alone had no significant effect on response
magnitude (P 5 0.31); however, there was a significant in-
teraction between OA status and occasion during the DNIC 2
(P 5 0.003) and post-DNIC (P 5 0.02) testing, which predicted
a higher magnitude of response (ie, decreased inhibition of
response) in OA dogs during these 2 occasions, compared with
control dogs. Inclusion of the overall interaction between OA
status and DNIC occasion as a predictor variable significantly
improved the model (change in log likelihood 5 7.82, df3; P 5
0.0499).
3.2.6.5. Effect of age
The effect of age was tested within models but found to be not
significant as either a main effect within the model, nor in
interaction with other terms within the models.
4. Discussion
These studies have shown that several characteristics of the CT
NWR were altered in dogs with OA, therefore central
neurophysiological changes may play a role in the pathology
Figure 5. Illustration of the mean curves predicted by the general linear model
for stimulus response of dogs within differing OA categories, assuming
a weight of 25 kg. Each data point for the control animals is based on 27 dogs;
for the OA group, it is based on 46 dogs; and for the OANSAID group, it is
based on 29 dogs. For each animal, the mean response to the 2 repetitions of
the stimulus response curve was averaged before analysis. The y-axis
represents the natural logarithm of the magnitude of the EMG response, and
the x-axis shows the magnitude of the stimulating current. EMG, electromy-
ography; OA, osteoarthritis; OANSAID, OA dogs receiving nonsteroidal anti-
inflammatory drug.
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of OA-associated pain and disability in dogs. Diffuse noxious
inhibitory control investigations suggest that these central
changes may be related in part to less effective descending
inhibition of nociceptive stimuli.
In man, the RIII (Ad-fibre-mediated) threshold is correlated with
the pain threshold35 and is decreased in painful OA states.12 We
anticipated that dogs exhibiting CS would demonstrate a di-
minished threshold to elicit an NWR; however, our results
indicated that threshold current was higher in OA animals
compared with controls. The underlying reason for this finding
is difficult to explain. The early latency (0-100 ms) response
elicited by NWR stimulation in our testing paradigm comprises
both Ab (RII equivalent in man) and Ad (RIII equivalent) trans-
mission. The RII response in man is considered non-nociceptive
and elicited by subpain threshold intensities of stimulation.
Central sensitisation may be accompanied by hypoaesthesia to
one or more sensory modalities in human subjects,18 therefore it
is possible that the greater threshold identified in OA dogs relates
to Ab-mediated hypoaesthesia. Although it may have been
desirable to further divide the responses by latency into Ab- or Ad-
mediated, as reported by Bergadano et al.,6 we undertook testing
in a mixed population of dogs with a range of weights and
conformations, which would have added to the variability in
response latency. Visual inspection of pilot data traces revealed
that we could only consistently identify an early (A-fibre) and late
(C-fibre) response.19 We could have considered measuring the
afferent distance of the conduction pathway in individual animals
and using this, together with an estimate of conduction velocity,
to calculate more accurately the latency window of the NWR in
each individual dog. However, our inclusion criteria for the study
limited the weight range of the dogs included in the study,
therefore this was not deemed necessary for the present
investigation.
The stimulus response curve demonstrated facilitation of the
early response in OANSAID dogs, compared with both control
andOA dogs. The amplitude of the RIII response has been shown
to correlate with the magnitude of subjective pain in conscious
human volunteers13; therefore, the inference from our data is that
Table 4
Effect size estimates and P values for the general linear model that was fitted to the temporal summation data.
Temporal summation early
response (lnmV/s)
SE Conf int
2.5%
Conf int
97.5%
P Temporal summation late
response (lnmV/s)
SE Conf int
2.5%
Conf int
97.5%
P
Intercept 24.900 0.341 25.569 24.231 ,0.001*** 27.142 0.700 28.513 25.771 ,0.001*
Weight 20.040 0.012 20.064 20.017 0.001** 0.017 0.015 20.012 0.046 0.246
OA 20.722 0.348 21.404 20.040 0.038*
OANSAID 20.254 0.362 20.964 0.456 0.483
Occasion 2 20.022 0.019 20.059 0.016 0.265 20.058 0.026 20.109 20.007 0.026*
Occasion 3 20.048 0.019 20.086 20.010 0.013* 20.120 0.026 20.171 20.069 ,0.001***
Stimulus
number
1.084 0.145 0.800 1.369 ,0.001*** 2.401 0.373 1.670 3.132 ,0.001***
Stimulus
number2
20.243 0.036 20.314 20.171 ,0.001*** 20.474 0.094 20.658 20.291 ,0.001***
Stimulus
number3
0.016 0.003 0.011 0.021 ,0.001*** 0.030 0.007 0.016 0.043 ,0.001***
Weight.
stimulus
number
20.014 0.005 20.024 20.003 0.009** 20.037 0.008 20.053 20.022 ,0.001***
Weight.
stimulus
number2
0.004 0.001 0.001 0.006 0.006** 0.008 0.002 0.004 0.012 ,0.001***
Weight.
stimulus
number3
0.000 0.000 0.000 0.000 0.009** 20.001 0.000 20.001 0.000 ,0.001***
OA.stimulus number — — — 0.805 0.186 0.442 1.169 ,0.001***
OANSAID.stimulus number — — — 0.540 0.193 0.161 0.919 0.005**
OA.stimulus number2 — — — 20.160 0.047 20.251 20.069 0.001**
OANSAID.stimulus number2 — — — 20.100 0.048 20.195 20.005 0.039*
OA.stimulus number3 — — — 0.010 0.003 0.004 0.017 0.003**
OANSAID.stimulus number3 — — — 0.006 0.004 20.001 0.013 0.079
Age — — — 0.088 0.067 20.043 0.218 0.187
Age.stimulus number — — — 20.121 0.036 20.190 20.051 0.001**
Age.stimulus number2 — — — 0.024 0.009 0.007 0.042 0.006**
Age.stimulus number3 — — — 20.002 0.001 20.003 0.000 0.016*
*P # 0.05; **P # 0.01; ***P # 0.001.
OA, osteoarthritis; OANSAID, OA dogs receiving nonsteroidal anti-inflammatory drug.
2326 J.R. Hunt et al.·159 (2018) 2318–2330 PAIN®
Copyright  2018 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.
OANSAID dogs may exhibit hyperalgesia, compared with dogs in
both the OA and control groups. The fact that the OA and
OANSAID groups were not different based on veterinarian
examination scores and radiographic OA scores were not
unexpected—there are no validated veterinarian assessment
systems of OA pain, and radiographic evidence of OA is known
not to be correlated with pain, just as in humans. Although OA
and OANSAID groups were comparable with respect to the
majority of the clinical metrology instrument data, OANSAIDs
were significantly more affectedwith respect to the CBPI pain and
the ACVS description of function subscales and had higher
scores on all the other validated clinical metrology instruments
(LOAD andCBPI function). These data indicate that theOANSAID
group was more severely affected by OA pain and suggest that
treatment with commonly prescribed veterinary NSAIDs20 may
not prevent or reverse CS, despite the tentative conclusion from
a recent study in humans with OA investigating etoricoxib.1 The
total duration of treatment with NSAIDs in the OANSAID group
was not recorded in individual dogs in this study, and it is possible
that differences in the duration of administration introduced
variability into the data. However, all dogs in the OANSAID group
had been receiving NSAIDs for at least 3 months before
recruitment to the study which, from early data in humans,1
would be sufficient time for the NSAID to exhibit an antihyper-
algesic effect.
Temporal summation data demonstrated no group differences
for the early (A-fibre-mediated) response but facilitation of the late
(mostly C-fibre) response in OA and OANSAID dogs, compared
with controls. The absence of an effect on the early response data
is likely due to a significant component being mediated by low-
threshold A-beta fibres. The applied 10-mA stimulus, designed
as a suprathreshold stimulus, would cause the early response to
saturate at this level of stimulation, and therefore, differences
between groups were minimised. By contrast, the higher-
threshold C-fibre-mediated late response displayed the expected
increasingmagnitude with repeated stimuli and, in alignment with
our hypothesis, was augmented in both OA and OANSAID
groups compared with the control group. This likely indicates that
OA is associated with CS in dogs. It is also possible that the EMG
findings for C-fibre-mediated responses are due to C-fiber
sensitisation rather than CS, although it is difficult to make
a distinction between these 2 effects in our data set.
The data produced during the DNIC investigation demonstrate
both that MCS elicits quantifiable DNIC in anaesthetised dogs,
and that the efficacy of DNIC is compromised in dogs with OA,
compared with a control group. A recent meta-analysis
concluded that, despite methodological limitations, a number of
chronic pain conditions in man, including OA, are associated with
reduced efficacy of CPM.28 Reduced net efficacy of nociceptive
inhibition may arise through impaired descending antinociceptive
modulation or through descending facilitation of nociceptive
signalling.3 We did not probe each of these pathways in-
dependently in these clinical cases; however, the magnitude of
measured EMG response in this study represents the net effect of
balance between inhibitory and facilitatory mechanisms; there-
fore, these data provide evidence that the balance of descending
pathways becomes shifted toward pronociception in canine OA.
The differences between OA and control groups were only
evident on DNIC 2, and then persisted into the post-DNIC period.
Because previous data on DNIC in dogs using MCS were not
available, numbers required to identify significant differences
were unknown; however, it is clear from our results that the
interaction between group and occasion begins to approach
significance during DNIC 1 (P 5 0.07). Had larger sample sizes
been used, we would have had greater power to detect
differences between groups, andmay have identified a significant
difference during DNIC 1. The small sample size is a major
limitation of the DNIC investigation and reflected difficulties in
establishing the methodology to elicit DNIC in dogs. Only 5
minutes was allowed to elapse between the TS protocol and the
start of the DNIC investigation. This time period was kept
deliberately short to avoid prolonging the anaesthesia time for the
dogs as far as possible. It is possible that delivery of
Figure 6. Illustration of themean curves predicted by the general linearmodel for
the first occasion temporal summation late response for dogswithin differing OA
categories, assuming aweight of 25 kg and age of 9 years. The y-axis represents
the natural logarithm of the magnitude of the EMG response, and the x-axis
shows stimulus number. EMG, electromyography; OA, osteoarthritis; OANSAID,
OA dogs receiving nonsteroidal anti-inflammatory drug.
Table 5
Demographic data.
Control (n 5 12) OA (n 5 11) P
Breed
Labrador 6 3 —
Collie 2 1 —
Retriever 2 2 —
Lurcher 2 1 —
German Shepherd 0 1 —
Rottweiler 0 2 —
Spaniel 0 1 —
Sex
Male neuter 6 5 1.0
Female neuter 6 6 1.0
Weight 23.8 (95%
CI 21.6-26.1)
31.3 (95%
CI 23.2-39.4)
0.053
Age 7.5 (95%
CI 6.9-8.2)
9.8 (95%
CI 8.5-11.1)
0.002**
Body condition score (0-9) 5 (4.25-5.75) 6 (5-7) 0.047*
*P # 0.05; **P # 0.01.
OA, osteoarthritis.
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Table 6
Musculoskeletal examination, owner-completedmetrology instrument, radiographic scoring, and nociceptivewithdrawal reflex
(NWR) data in dogs undergoing the DNIC protocol.
Control OA P
Lameness (0-10) 0 (0-0) 3 (3-3) ,0.001***
Mobility (0-3) 0 (0-0) 1 (1-2) ,0.001***
OA score (0-192) 0 (0-2) 9 (6-12) ,0.001***
Joint pain score (0-48) 0 (0-0) 4 (2-5) ,0.001***
CBPI pain (0-10) 0 (0-0) 1.125 (0-2.69) 0.0085**
CBPI function (0-10) 0 (0-0) 2.375 (0-6.938) 0.0022**
HCPI (0-44) 1 (0-1.75) 15.5 (3.5-20.5) 0.0026**
ACVS stiffness (0-16) 0 (0-0) 5.5 (0-7) 0.0029**
ACVS function (0-16) 0 (0-0) 4 (0-8.75) 0.0076**
ACVS gait (0-20) 0 (0-0) 5 (2.25-11.5) 0.0022**
ACVS QoL (0-12) 0 (0-0.75) 3 (0-6.25) 0.0076**
LOAD (0-52) 2.5 (0-3) 15.5 (5-25) 0.0042**
SNoRE 13.5 (10.5-18.5) 15.5 (14-25.25) 0.21
Radiographic OA score (0-70) 2 (0.25-3) 20 (16-28) ,0.001***
Number of joints radiographically affected 1 (0.25-2) 5 (2-6) ,0.001***
NWR threshold 1.9 (95% CI 1.4-2.5) 3.8 (95% CI 2.4-5.2) 0.013*
*P # 0.05; **P # 0.01; ***P # 0.001.
CBPI, Canine Brief Pain Inventory; CI, confidence interval; DNIC, diffuse noxious inhibitory control; HCPI, Helsinki Chronic Pain Index; LOAD, Liverpool Osteoarthritis in Dogs; OA, osteoarthritis; SNoRE, sleep and night time
restlessness evaluation.
Table 7
Parameter estimates, SE, 95% CIs, and P values for the general linear model fitted to the stimulus response (early) data
(ln(mV/s)).
Predictor variable Parameter estimate SE Conf int 2.5% Conf int 97.5% P
Fixed effects
Cons 25.420132 0.265083 25.939685 24.90058 ,0.001***
DNIC 1 20.158861 0.095373 20.345789 0.028067 0.048*
DNIC 2 20.508912 0.095373 20.695839 20.321984 ,0.001***
Post-DNIC 20.433574 0.100943 20.631419 20.235729 ,0.001***
Time 20.009741 0.006579 20.022635 0.003153 0.069
Time2 20.000054 0.000418 20.000873 0.000764 0.448
Time3 0.000005 0.000007 20.00001 0.000019 0.265
OA 20.183357 0.381486 20.931054 0.564341 0.315
OA.DNIC 1 0.181664 0.127397 20.068029 0.431357 0.077
OA.DNIC 2 0.349945 0.127397 0.100251 0.599638 0.003**
OA.post-DNIC 0.271047 0.131377 0.013553 0.528541 0.020**
Time.DNIC 1 20.055631 0.009303 20.073866 20.037397 ,0.001***
Time2.DNIC 1 0.003449 0.000591 0.002291 0.004607 ,0.001***
Time3.DNIC 1 20.000052 0.00001 20.000072 20.000032 ,0.001***
Time.DNIC 2 20.05043 0.009303 20.068664 20.032195 ,0.001***
Time2.DNIC 2 0.00353 0.000591 0.002372 0.004688 ,0.001***
Time3.DNIC 2 20.000057 0.00001 20.000077 20.000037 ,0.001***
Time.post-DNIC 0.000054 0.009522 20.01861 0.018717 0.497
Time2.post-DNIC 0.000264 0.000605 20.000922 0.001449 0.331
Time3.post-DNIC 20.000006 0.00001 20.000026 0.000015 0.299
*P # 0.05; **P # 0.01; ***P # 0.001.
CI, confidence interval; DNIC, diffuse noxious inhibitory control; OA, osteoarthritis.
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a supramaximal stimulus during the TS protocol sensitised the
nociceptive system so that the nociceptive pathways were not in
a naive state at the start of the DNIC experiment, and this may
have affected our DNIC results. The optimal time delay between
TS and measurement of DNIC is currently unknown.
Nociceptive withdrawal reflexes are segmental spinal reflexes,
subject to supraspinal modulation.11 Alfaxalone anaesthesia
enabled NWR recording in client-owned dogs. While alfaxalone
increases NWR threshold and decreases magnitude of response
to electrical stimulation,19 there is no reason to expect
a differential effect of the anaesthetic on control vs OA or
OANSAID animals, as alfaxalone is devoid of analgesic activity.39
Regarding assessment of DNIC, many sedatives and analge-
sics will interact with descending pronociceptive and antinoci-
ceptive pathways27,36 and could alter the measured responses.
Acepromazine has been shown not to modulate NWR7 and,
given it is considered to have no antinociceptive properties,4
would not be expected to interact with descending modulatory
mechanisms. Alfaxalone is a gamma aminobutyric acid agonist,
and DNIC is reportedly unaffected by gamma aminobutyric acid
agonists,23 therefore we consider that the form of anaesthesia
used was appropriate to our investigation.
Although we have identified group-level differences in DNIC
efficacy, the aim is ultimately to identify individuals in which
decreased DNIC efficacy contributes to the pain phenotype and
address this mechanism therapeutically.3 Determining a normal
“range” of DNIC responses in dogs will require the study of
additional numbers of dogs of a wider demographic, particularly
in view of the inconsistently reported sex32 and age25 differences
associated with CPM in man.
In conclusion, we have demonstrated a number of neurophys-
iological changes indicative of CS processes in dogs affected by
spontaneous OA, consistent with findings in man. However,
measurement of electrical thresholds seemed not to be a suitable
parameter for CS using the current methods. The mechanisms
involved may encompass both upregulation of nociceptive
afferent pathways,26 in addition to alterations in the balance of
descending modulatory mechanisms as shown here. Increas-
ingly, it seems that the pathophysiological mechanisms of human
OA21 are shared by the spontaneous disease in dogs, further
validating canine spontaneous OA as a model for the human
disease31,38 and supporting the use of dogs for mechanistic
clinical trials to advance therapeutic development in humans.
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